Author
Merck & Co., Inc., Rahway, NJ, USA (United States)
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
3 papers
Recent·Most cited
Noah Lubben, Julia K. Brynildsen, Connor M. Webb…·Michael X. Henderson
This study shows that LRRK2 kinase inhibition reverses tau pathology progression in mice with the G2019S mutation but not in wildtype mice.
Cheryl E. G. Leyns, Alice Prigent, Brenna Beezhold…·Michael X. Henderson
The paper examines the relationship between glucocerebrosidase activity, lipid levels, and protein pathologies in Parkinson's disease and dementia with Lewy bodies.
Marco A.S. Baptista, Kalpana Merchant, Ted Barrett…·Todd B. Sherer
This study evaluates the lung effects of LRRK2 kinase inhibitors in non-human primates, finding reversible histopathological changes without pulmonary function deficits.